Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

Inclusion Criteria: * Diagnosis of VMT/sVMA, with evidence of focal VMT visible on Spectral Domain - Optical Coherence Tomography (SD-OCT). * Read, sign, and date an Institutional Review Board/Ethics Committee-approved informed consent form. * Willing and able to attend all study visits. * Other protocol-specified inclusion criteria may apply. Exclusion Criteria: * Women of childbearing potential if pregnant, test positive on a urine pregnancy test, intend to become pregnant during the study period, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study. * Hypersensitivity to ocriplasmin or any of the JETREA™® excipients. * Active or suspected intraocular or periocular infection in either eye. * Participation in any interventional clinical trial within 30 days prior to baseline. * Presence of epiretinal membrane (ERM) over the macula at baseline in the study eye. * Broad VMT/VMA \> 1500 microns at baseline in the study eye. * History of vitrectomy in the study eye. * History of laser photocoagulation to the macula in the study eye. * Any relevant concomitant ocular condition in the study eye that, in the opinion of the Investigator, could be expected to worsen or require surgical intervention during the study period. * Macular hole of \> 400 microns diameter in the study eye. * High myopia in the study eye. * Pseudo-exfoliation, Marfan's syndrome, phacodonesis, or any other finding in the study eye that, in the In…